Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A00500 | Pages: 210 | Charts: 60 | Tables: 84 |
The early toxicity testing market accounted for $739 million in 2017, and is expected to reach $1,301 million by 2025, registering a CAGR of 7.3% from 2018 to 2025.Toxicity is the degree of threat posed by a substance to the living organism. The effects of chemical substance on the body are studied to choose a potential drug candidate during the development of newer molecules. Early toxicity testing is carried out at pre-clinical stages of a drug development process and is essential as toxicity serves as the major reason for the failure of potential drug candidates in the later stages of drug development leading to huge financial loss to companies. Well designed and executed preclinical studies are critical to the success of any drug development program. Therefore, they must reliably assess the safety of a new drug entity, laying the groundwork for clinical trials and ultimately, regulatory approval. Moreover, these tests are necessary as they can prevent financial losses that occur during the failure of drugs in further late stages of drug development.
The global early toxicity testing market is expected to witness significant growth during the forecast period, owing to increase in the R&D activities and rise in stringent regulatory authorities concerning public healthcare welfare. In addition, technological advancements in in vitro technique, rise in adoption of in vitro models in the global early toxicity testing industry worldwide, and surge in adoption of early toxicity testing in the various industries further fuel the market growth. However, limitations associated with preclinical testing hamper the market growth. Furthermore, the technological advancements related to early toxicity testing provide opportunities for the growth of the early toxicity testing market during the forecast period.
Early Toxicity Testing Market Segmentation
The early toxicity testing market is segmented based on technique, end user, and region to provide a detailed assessment of the market. Based on technique, the market is divided into in vivo, in vitro, and in silico. Based on in vitro, it is further divided into in vitro toxicity testing market by assays and in vitro toxicity testing market by toxicity endpoints. The in vitro toxicity testing market by assays is further segmented into enzyme toxicity assays, bacterial toxicity assays, cell-based ELISA & western blots, receptor binding assays, and other assays. The in vitro toxicity testing market by toxicity endpoints is further divided into dermal toxicity, systemic toxicity, carcinogenicity, ocular toxicity, skin sensitization and irritation, neurotoxicity, organ toxicity, and other toxicity endpoints. By end user, it is categorized into pharmaceutical industry, food industry, chemicals industry, cosmetics industry, and other industry. Based on region, the early toxicity testing market size is analyzed across North America (U.S., Canada and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa and rest of LAMEA).
Get more information on this report : Request Sample Pages
Segment review
Based on technique, the market is divided into in vivo, in vitro, and in silico. The in vitro segment was the largest contributor to the early toxicity testing market in 2017 and is expected to maintain its dominant position throughout the analysis period. In vitro toxicity methods use different laboratory techniques and cell lines to assess the possible adverse effects of different drugs and chemicals on the human health. Cost-effective nature of this technique, technological advancement, and stringent regulation for animal usage during diagnostic procedures majorly drive the growth of the early toxicity testing market growth. On the other side, the in silico segment is the fastest growing segment during the forecast period, owing to the rise in its adoption due to advantages offered by the technique. In silico techniques have revolutionized the drug discovery process as these techniques are not only applied to find the new targets and new molecule with high affinity to those targets but also used to determine the metabolic pathways of those active molecules. In addition, these techniques are computer-based that eliminate animal sacrifice, which is another factor that contributes toward the early toxicity testing market growth.
Get more information on this report : Request Sample Pages
According to the early toxicity testing market analysis, the end users segment is classified into pharmaceutical industry, food industry, chemicals industry, cosmetics industry, and other industries. The pharmaceutical segment occupied the highest share of early toxicity testing market size in the year 2017. Cosmetic industry segment registered fastest growth rate during forecast period, owing to rise in aesthetic consciousness, surge in disposable income of general public across the globe, increase in new product launches in the field of cosmetics and stringent government guidelines monitoring the nature of chemicals used in cosmetic products.
Get more information on this report : Request Sample Pages
Region wise, Europe accounted for the largest early toxicity testing market share in 2017 owing to surge in R&D related to drug discovery and stringent guidelines regulating the safety of chemicals used in different products used by public. Other factors that fuel the growth of the market in this region include the wide and easy availability of toxicity testing devices and products and presence of highly trained technical professionals. Asia-Pacific is expected to register the fastest growth during the forecast period due to rise in awareness related to toxicity of compounds and rise in R&D investments related to healthcare.
Get more information on this report : Request Sample Pages
Key Market Segments
Key Market Players
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Top player positioning, 2017
3.4. Porter’s five forces analysis
3.5. Government regulations
3.6. Market dynamics
3.6.1. Drivers
3.6.1.1. Surge in R&D activities in healthcare
3.6.1.2. Rise in adoption of in vitro model
3.6.1.3. Increase in stringency of regulatory authorities concerning public healthcare welfare
3.6.1.4. Surge in adoption of early toxicity testing
3.6.2. Restraint
3.6.2.1. Limitations of preclinical testing
3.6.3. Opportunity
3.6.3.1. Technological advancement in the field of early toxicity testing
3.6.4. Impact analysis
CHAPTER 4: EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
4.1. Overview
4.1.1. Market size and forecast
4.2. In Vivo
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. In Vitro
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.3.4. In vitro early toxicity testing market, by assay
4.3.4.1. Enzyme toxicity assays
4.3.4.1.1. Market size and forecast
4.3.4.2. Bacterial toxicity assays
4.3.4.2.1. Market size and forecast
4.3.4.3. Cell-based ELISA and western blots
4.3.4.3.1. Market size and forecast
4.3.4.4. Tissue culture assays
4.3.4.4.1. Market size and forecast
4.3.4.5. Receptor binding assays
4.3.4.5.1. Market size and forecast
4.3.4.6. Others
4.3.4.6.1. Market size and forecast
4.3.5. In vitro early toxicity testing market, by toxicity end-point
4.3.5.1. Dermal toxicity
4.3.5.1.1. Market size and forecast
4.3.5.2. Systemic toxicity
4.3.5.2.1. Market size and forecast
4.3.5.3. Carcinogenicity
4.3.5.3.1. Market size and forecast
4.3.5.4. Ocular toxicity
4.3.5.4.1. Market size and forecast
4.3.5.5. Skin sensitization and irritation
4.3.5.5.1. Market size and forecast
4.3.5.6. Genotoxicity
4.3.5.6.1. Market size and forecast
4.3.5.7. Neurotoxicity
4.3.5.7.1. Market size and forecast
4.3.5.8. Organ toxicity
4.3.5.8.1. Market size and forecast
4.3.5.9. Others
4.3.5.9.1. Market size and forecast
4.4. In silico
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
CHAPTER 5: EUROPE EARLY TOXICITY TESTING MARKET, BY END USER
5.1. Overview
5.1.1. Market size and forecast
5.2. Pharmaceutical industry
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Food industry
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Chemicals industry
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Cosmetic industry
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country
5.6. Others
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country
CHAPTER 6: EARLY TOXICITY TESTING MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. early toxicity testing market, by technique type
6.2.2.1.2. U.S. early toxicity testing market, by end user
6.2.2.2. Canada
6.2.2.2.1. Canada early toxicity testing market, by technique type
6.2.2.2.2. Canada early toxicity testing market, by end user
6.2.2.3. Mexico
6.2.2.3.1. Mexico early toxicity testing market, by technique type
6.2.2.3.2. Mexico early toxicity testing market, by end user
6.2.3. Market size and forecast, by technique type
6.2.4. Market size and forecast, by end user
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast, by country
6.3.2.1. Germany
6.3.2.1.1. Germany early toxicity testing market, by technique type
6.3.2.1.2. Germany early toxicity testing market, by end user
6.3.2.2. France
6.3.2.2.1. France early toxicity testing market, by technique type
6.3.2.2.2. France early toxicity testing market, by end user
6.3.2.3. UK
6.3.2.3.1. UK early toxicity testing market, by technique type
6.3.2.3.2. UK early toxicity testing market, by end user
6.3.2.4. Rest of Europe
6.3.2.4.1. Rest of Europe early toxicity testing market, by technique type
6.3.2.4.2. Rest of Europe early toxicity testing market, by end user
6.3.3. Market size and forecast, by technique type
6.3.4. Market size and forecast, by end user
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast, by country
6.4.2.1. Japan
6.4.2.1.1. Japan early toxicity testing market, by technique type
6.4.2.1.2. Japan early toxicity testing market, by end user
6.4.2.2. China
6.4.2.2.1. China early toxicity testing market, by technique type
6.4.2.2.2. China early toxicity testing market, by end user
6.4.2.3. Australia
6.4.2.3.1. Australia early toxicity testing market, by technique type
6.4.2.3.2. Australia early toxicity testing market, by end user
6.4.2.4. India
6.4.2.4.1. India early toxicity testing market, by technique type
6.4.2.4.2. India early toxicity testing market, by end user
6.4.2.5. Rest of Asia-Pacific
6.4.2.5.1. Rest of Asia-Pacific early toxicity testing market, by technique type
6.4.2.5.2. Rest of Asia-Pacific early toxicity testing market, by end user
6.4.3. Market size and forecast, by technique type
6.4.4. Market size and forecast, by end user
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. Market size and forecast, by country
6.5.2.1. Brazil
6.5.2.1.1. Brazil early toxicity testing market, by technique type
6.5.2.1.2. Brazil early toxicity testing market, by end user
6.5.2.2. South Africa
6.5.2.2.1. South Africa early toxicity testing market, by technique type
6.5.2.2.2. South Africa early toxicity testing market, by end user
6.5.2.3. Rest of LAMEA
6.5.2.3.1. xx early toxicity testing market, by technique type
6.5.2.3.2. rest of LAMEA early toxicity testing market, by end user
6.5.3. Market size and forecast, by technique type
6.5.4. Market size and forecast, by end user
CHAPTER 7: COMPANY PROFILES
7.1. AGILENT TECHNOLOGIES, INC.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product type Portfolio
7.1.5. Business performance
7.2. BIOANALYTICAL SYSTEMS, INC.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.3. BRUKER CORPORATION
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.4. DANAHER CORPORATION (BECKMAN COULTER, INC.)
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product type portfolio
7.4.5. Business performance
7.5. EVOTEC AG (CYPROTEX)
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.6. ENZO BIOCHEM, INC. (ENZO CLINICAL LABS, INC.)
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product Portfolio
7.6.5. Business performance
7.7. GENERAL ELECTRIC COMPANY (GE HEALTHCARE)
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.8. MYRIAD GENETICS, INC. (MYRIAD RBM.)
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Product Portfolio
7.8.4. Business performance
7.9. PERKINELMER INC.
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product Portfolio
7.9.5. Business performance
7.10. THERMO FISHER SCIENTIFIC, INC.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product Portfolio
7.10.5. Business performance
LIST OF TABLES
TABLE 01. GLOBAL EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2017–2025 ($MILLION)
TABLE 02. GLOBAL IN VIVO EARLY TOXICITY TESTING MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 03. GLOBAL IN VITRO EARLY TOXICITY TESTING MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 04. IN VITRO EARLY TOXICITY TESTING MARKET, BY ASSAYS, 2017–2025 ($MILLION)
TABLE 05. IN VITRO EARLY TOXICITY TESTING MARKET, BY TOXICITY END-POINT, 2017–2025 ($MILLION)
TABLE 06. GLOBAL IN SILICO EARLY TOXICITY TESTING MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 07. EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025 ($MILLION)
TABLE 08. EARLY TOXICITY TESTING MARKET FOR PHARMACEUTICAL INDUSTRY, BY REGION, 2017–2025 ($MILLION)
TABLE 09. EARLY TOXICITY TESTING MARKET FOR FOOD INDUSTRY, BY REGION, 2017–2025 ($MILLION)
TABLE 10. EARLY TOXICITY TESTING MARKET FOR CHEMICAL INDUSTRY, BY REGION, 2017–2025 ($MILLION)
TABLE 11. EARLY TOXICITY TESTING MARKET FOR COSMETIC INDUSTRY, BY REGION, 2017–2025 ($MILLION)
TABLE 12. EARLY TOXICITY TESTING MARKET FOR OTHER INDUSTRIES, BY REGION, 2017–2025 ($MILLION)
TABLE 13. EARLY TOXICITY TESTING MARKET REVENUE, BY REGION, 2017–2025 ($MILLION)
TABLE 14. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 15. U.S. EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 16. U.S. EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 17. CANADA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 18. CANADA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 19. MEXICO EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 20. MEXICO EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 21. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 22. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 23. EUROPE EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 24. GERMANY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 25. GERMANY EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 26. FRANCE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 27. FRANCE EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 28. UK EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 29. UK EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 30. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 31. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 32. EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 33. EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 34. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 35. JAPAN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 36. JAPAN EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 37. CHINA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 38. CHINA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 39. AUSTRALIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 40. AUSTRALIA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 41. INDIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 42. INDIA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 43. REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 44. REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 45. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 46. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 47. LAMEA EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 48. BRAZIL EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 49. BRAZIL EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 50. SOUTH AFRICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 51. SOUTH AFRICA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 52. REST OF LAMEA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 53. REST OF LAMEA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 54. LAMEA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 55. LAMEA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 56. AGILENT: COMPANY SNAPSHOT
TABLE 57. AGILENT: OPERATING SEGMENTS
TABLE 58. AGILENT: PRODUCT TYPE PORTFOLIO
TABLE 59. BASI: COMPANY SNAPSHOT
TABLE 60. BASI: OPERATING SEGMENTS
TABLE 61. BASI: PRODUCT PORTFOLIO
TABLE 62. BRUKER: COMPANY SNAPSHOT
TABLE 63. BRUKER: OPERATING SEGMENTS
TABLE 64. BRUKER: PRODUCT PORTFOLIO
TABLE 65. DANAHER: COMPANY SNAPSHOT
TABLE 66. DANAHER: OPERATING SEGMENTS
TABLE 67. DANAHER: PRODUCT TYPE PORTFOLIO
TABLE 68. EVOTEC: COMPANY SNAPSHOT
TABLE 69. EVOTEC: OPERATING SEGMENTS
TABLE 70. EVOTEC: PRODUCT PORTFOLIO
TABLE 71. ENZO: COMPANY SNAPSHOT
TABLE 72. ENZO: OPERATING SEGMENTS
TABLE 73. ENZO: PRODUCT PORTFOLIO
TABLE 74. GE HEALTHCARE: COMPANY SNAPSHOT
TABLE 75. GE HEALTHCARE: OPERATING SEGMENTS
TABLE 76. GE HEALTHCARE: PRODUCT PORTFOLIO
TABLE 77. MYRIAD: COMPANY SNAPSHOT
TABLE 78. MYRIAD: PRODUCT PORTFOLIO
TABLE 79. PERKINELMER: COMPANY SNAPSHOT
TABLE 80. PERKINELMER: OPERATING SEGMENTS
TABLE 81. PERKINELMER: PRODUCT PORTFOLIO
TABLE 82. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
TABLE 83. THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS
TABLE 84. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. GLOBAL EARLY TOXICITY TESTING MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS, 2017
FIGURE 03. TOP PLAYER POSITIONING, 2017
FIGURE 04. MODERATE BARGANING POWER OF BUYERS
FIGURE 05. MODERATE BARGANING POWER OF SUPPLIERS
FIGURE 06. MODERATE THREAT OF SUBSTITUTION
FIGURE 07. LOW THREAT OF NEW ENTRANTS
FIGURE 08. HIGH COMPETITIVE RIVALRY
FIGURE 09. IMPACT ANALYSES, GLOBAL EARLY TOXICITY TESTING MARKET
FIGURE 10. COMPARATIVE ANALYSIS OF IN VIVO EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017 & 2025
FIGURE 11. COMPARATIVE ANALYSIS OF IN VITRO EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017 & 2025
FIGURE 12. ENZYME TOXICITY ASSASYS MARKET, 2017–2025 ($MILLION)
FIGURE 13. BACTERIAL TOXICITY ASSAYS MARKET, 2017–2025 ($MILLION)
FIGURE 14. CELL-BASED ELISA & WESTERN BLOTS MARKET, 2017–2025 ($MILLION)
FIGURE 15. TISSUE CULTURE ASSAYS MARKET, 2017–2025 ($MILLION)
FIGURE 16. RECEPTOR BINDING ASSAYS MARKET, 2017–2025 ($MILLION)
FIGURE 17. ASSAYS MARKET FOR OTHERS, 2017–2025 ($MILLION)
FIGURE 18. DERMAL TOXICITY MARKET, 2017–2025 ($MILLION)
FIGURE 19. SYSTEMIC TOXICITY MARKET, 2017–2025 ($MILLION)
FIGURE 20. CARCINOGENICITY MARKET, 2017–2025 ($MILLION)
FIGURE 21. OCULAR TOXICITY MARKET, 2017–2025 ($MILLION)
FIGURE 22. SKIN SENSITIZATION AND IRRITATION MARKET, 2017–2025 ($MILLION)
FIGURE 23. GENOTOXICITY MARKET, 2017–2025 ($MILLION)
FIGURE 24. NEUROTOXICITY MARKET, 2017–2025 ($MILLION)
FIGURE 25. ORGAN TOXICITY MARKET, 2017–2025 ($MILLION)
FIGURE 26. TOXICITY ENDPOINTS MARKET FOR OTHERS, 2017–2025 ($MILLION)
FIGURE 27. COMPARATIVE ANALYSIS OF IN SILICO EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017 & 2025
FIGURE 28. COMPARATIVE ANALYSIS OF EARLY TOXICITY TESTING MARKET FOR PHARMACEUTICAL INDUSTRY, BY COUNTRY, 2017 & 2025
FIGURE 29. COMPARATIVE ANALYSIS OF EARLY TOXICITY TESTING MARKET FOR FOOD INDUSTRY, BY COUNTRY, 2017 & 2025
FIGURE 30. COMPARATIVE ANALYSIS OF EARLY TOXICITY TESTING MARKET FOR CHEMICAL INDUSTRY, BY COUNTRY, 2017 & 2025
FIGURE 31. COMPARATIVE ANALYSIS OF EARLY TOXICITY TESTING MARKET FOR COSMETIC INDUSTRY, BY COUNTRY, 2017 & 2025
FIGURE 32. COMPARATIVE ANALYSIS OF EARLY TOXICITY TESTING MARKET FOR OTHER INDUSTRIES, BY COUNTRY, 2017 & 2025
FIGURE 33. AGILENT: REVENUE, 2016–2018 ($MILLION)
FIGURE 34. AGILENT: REVENUE SHARE BY OPERATING SEGMENT, 2018 (%)
FIGURE 35. AGILENT: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 36. BASI: NET SALES, 2016–2018 ($MILLION)
FIGURE 37. BASI: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 38. BASI: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 39. BRUKER: NET SALES, 2016–2018 ($MILLION)
FIGURE 40. BRUKER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 41. BRUKER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 42. DANAHER: NET SALES, 2016–2018 ($MILLION)
FIGURE 43. DANAHER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 44. DANAHER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 45. EVOTEC: NET SALES, 2016–2018 ($MILLION)
FIGURE 46. EVOTEC: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 47. EVOTEC: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 48. ENZO: NET SALES, 2016–2018 ($MILLION)
FIGURE 49. ENZO: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 50. GE HEALTHCARE: NET SALES, 2016–2018 ($MILLION)
FIGURE 51. GE HEALTHCARE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 52. GE HEALTHCARE: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 53. MYRIAD: NET SALES, 2016–2018 ($MILLION)
FIGURE 54. MYRIAD: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 55. PERKINELMER: NET SALES, 2016–2018 ($MILLION)
FIGURE 56. PERKINELMER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 57. PERKINELMER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 58. THERMO FISHER SCIENTIFIC: REVENUE, 2016–2018 ($MILLION)
FIGURE 59. THERMO FISHER SCIENTIFIC: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 60. THERMO FISHER SCIENTIFIC: REVENUE SHARE BY REGION, 2018 (%)